JPWO2021168290A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021168290A5 JPWO2021168290A5 JP2022549759A JP2022549759A JPWO2021168290A5 JP WO2021168290 A5 JPWO2021168290 A5 JP WO2021168290A5 JP 2022549759 A JP2022549759 A JP 2022549759A JP 2022549759 A JP2022549759 A JP 2022549759A JP WO2021168290 A5 JPWO2021168290 A5 JP WO2021168290A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nucleic acid
- cationic lipid
- composition according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 37
- 239000002105 nanoparticle Substances 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 125000002091 cationic group Chemical group 0.000 claims 11
- 239000000232 Lipid Bilayer Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 8
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 8
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 8
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 8
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 8
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 8
- 210000004443 dendritic cell Anatomy 0.000 claims 6
- 210000000265 leukocyte Anatomy 0.000 claims 6
- 102100035703 Prostatic acid phosphatase Human genes 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims 4
- -1 cationic lipid Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 208000028919 diffuse intrinsic pontine glioma Diseases 0.000 claims 1
- 208000026144 diffuse midline glioma, H3 K27M-mutant Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978694P | 2020-02-19 | 2020-02-19 | |
| US62/978,694 | 2020-02-19 | ||
| PCT/US2021/018831 WO2021168290A1 (en) | 2020-02-19 | 2021-02-19 | Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515927A JP2023515927A (ja) | 2023-04-17 |
| JPWO2021168290A5 true JPWO2021168290A5 (https=) | 2024-02-27 |
| JP2023515927A5 JP2023515927A5 (https=) | 2024-02-27 |
Family
ID=77392250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549759A Pending JP2023515927A (ja) | 2020-02-19 | 2021-02-19 | 免疫チェックポイント阻害剤による治療に対して腫瘍を感作させる多重膜ｒｎａナノ粒子および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230346700A1 (https=) |
| EP (1) | EP4106730A4 (https=) |
| JP (1) | JP2023515927A (https=) |
| AU (1) | AU2021222036A1 (https=) |
| CA (1) | CA3168509A1 (https=) |
| WO (1) | WO2021168290A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3999034A4 (en) * | 2019-07-19 | 2023-08-23 | University Of Florida Research Foundation, Incorporated | Multilamellar rna nanoparticles |
| WO2023196232A1 (en) * | 2022-04-04 | 2023-10-12 | University Of Florida Research Foundation, Inc. | Method of characterizing tumors |
| WO2025207807A1 (en) * | 2024-03-27 | 2025-10-02 | The University Of Florida Research Foundation, Inc. | Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer |
| WO2025207936A1 (en) * | 2024-03-28 | 2025-10-02 | Mirror Biologics, Inc. | Treatment for colorectal cancer using immune checkpoint inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3364949A4 (en) * | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| KR102469450B1 (ko) * | 2016-05-18 | 2022-11-22 | 모더나티엑스, 인크. | 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도 |
| CA3050614A1 (en) * | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| WO2019222400A2 (en) * | 2018-05-15 | 2019-11-21 | Dnalite Therapeutics, Inc. | Mucus-penetrating peptides, delivery vehicles and methods of therapy |
| WO2020037102A1 (en) * | 2018-08-15 | 2020-02-20 | University Of Florida Research Foundation, Inc. | Methods of sensitizing tumors to treatment with immune checkpoint inhibitors |
| EP3999034A4 (en) * | 2019-07-19 | 2023-08-23 | University Of Florida Research Foundation, Incorporated | Multilamellar rna nanoparticles |
-
2021
- 2021-02-19 US US17/800,687 patent/US20230346700A1/en active Pending
- 2021-02-19 WO PCT/US2021/018831 patent/WO2021168290A1/en not_active Ceased
- 2021-02-19 CA CA3168509A patent/CA3168509A1/en active Pending
- 2021-02-19 EP EP21756388.1A patent/EP4106730A4/en active Pending
- 2021-02-19 AU AU2021222036A patent/AU2021222036A1/en active Pending
- 2021-02-19 JP JP2022549759A patent/JP2023515927A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | Nucleic acid drug vectors for diagnosis and treatment of brain diseases | |
| JP6023126B2 (ja) | 標的遺伝子の発現を抑制する組成物 | |
| Merkel et al. | Nonviral siRNA delivery to the lung: Investigation of PEG− PEI polyplexes and their in vivo performance | |
| Gao et al. | Research progress on siRNA delivery with nonviral carriers | |
| CN112823811B (zh) | 一种跨越血脑屏障和特异性靶向脑胶质瘤治疗药物的投递系统的制备方法 | |
| Tagami et al. | Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA | |
| Lu et al. | Environment‐responsive lipid/siRNA nanoparticles for cancer therapy | |
| JP2025138644A5 (https=) | ||
| US20200188424A1 (en) | Compositions and methods for the treatment of fibrotic diseases | |
| JP2021523145A5 (https=) | ||
| CN115141829A (zh) | 一种基因线路、rna递送系统及其应用 | |
| CN115141844A (zh) | 一种rna质粒递送系统及其应用 | |
| CN115245572B (zh) | 靶向抑制肝细胞pcsk9降低ldlc的仿生纳米颗粒材料及其应用 | |
| WO2017067188A1 (zh) | 一种药物组合物及其应用 | |
| Soleimani et al. | CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice | |
| WO2021016106A8 (en) | Multilamellar rna nanoparticles | |
| WO2007080902A1 (ja) | 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤 | |
| JPWO2021168290A5 (https=) | ||
| KR20230144472A (ko) | 대식세포 유래 소포로 코팅된 지질 나노입자 및 이의 제조 방법 | |
| Berton et al. | Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular BioVector (SMBV) | |
| Tabasi et al. | Transitional insight into the RNA-based oligonucleotides in cancer treatment | |
| CN119405823B (zh) | 一种基于g四链体rna的蛋白降解靶向嵌合体及其制备方法与应用 | |
| CN115137834A (zh) | 一种用于治疗胶质母细胞瘤的rna质粒递送系统 | |
| JPWO2021158996A5 (https=) | ||
| JPWO2019217593A5 (https=) |